"Gelatinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of enzymes that catalyzes the degradation of gelatin by acting on the peptide bonds. EC 3.4.24.-.
| Descriptor ID |
D018093
|
| MeSH Number(s) |
D08.811.277.656.300.480.252 D08.811.277.656.675.374.252
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Gelatinases".
Below are MeSH descriptors whose meaning is more specific than "Gelatinases".
This graph shows the total number of publications written about "Gelatinases" by people in this website by year, and whether "Gelatinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 1 | 2 |
| 1995 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 3 | 3 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gelatinases" by people in Profiles.
-
Jackson KW, Christiansen VJ, Yadav VR, Silasi-Mansat R, Lupu F, Awasthi V, Zhang RR, McKee PA. Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase. Neoplasia. 2015 Jan; 17(1):43-54.
-
Christiansen VJ, Jackson KW, Lee KN, Downs TD, McKee PA. Targeting inhibition of fibroblast activation protein-a and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments. Neoplasia. 2013 Apr; 15(4):348-58.
-
Lee WH, Warrington JP, Sonntag WE, Lee YW. Irradiation alters MMP-2/TIMP-2 system and collagen type IV degradation in brain. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):1559-66.
-
Lee KN, Jackson KW, Christiansen VJ, Dolence EK, McKee PA. Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor a2-antiplasmin. J Thromb Haemost. 2011 May; 9(5):987-96.
-
Lee KN, Jackson KW, Terzyan S, Christiansen VJ, McKee PA. Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design. Biochemistry. 2009 Jun 16; 48(23):5149-58.
-
Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, McKee PA. Why alpha-antiplasmin must be converted to a derivative form for optimal function. J Thromb Haemost. 2007 Oct; 5(10):2095-104.
-
Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K, Christiansen VJ, McKee PA, Egleston B, Cohen SJ, Weiner LM, Meropol NJ, Cheng JD. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. . 2007 Nov; 6(11):1691-9.
-
Jog NR, Rane MJ, Lominadze G, Luerman GC, Ward RA, McLeish KR. The actin cytoskeleton regulates exocytosis of all neutrophil granule subsets. . 2007 May; 292(5):C1690-700.
-
Christiansen VJ, Jackson KW, Lee KN, McKee PA. Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys. 2007 Jan 15; 457(2):177-86.
-
Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, McKee PA. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood. 2006 Feb 15; 107(4):1397-404.